Am J Perinatol . Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019

[tetano]

Am J Perinatol


. 2023 Apr 18.
doi: 10.1055/s-0042-1753488. Online ahead of print.
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019


Antonio Riccardo Buonomo ¹ , Isabella Di Filippo ¹ , Nunzia Esposito ¹ , Gabriele Saccone ² , Mariano Nobile ¹ , Giulio Viceconte ¹ , Riccardo Villari ² , Costantino Di Carlo ² , Giuseppe Bifulco ² , Ivan Gentile ¹



Affiliations

• PMID: 37072016
• DOI: 10.1055/s-0042-1753488

Abstract

Objective: The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
Study design: We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.
Results: Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.
Conclusion: Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.
Key points: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..